The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Metal ions, Alzheimer's disease and chelation therapy
Open accessAbstract
Metal ions, Alzheimer's disease and chelation therapy: In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is known to transfer metal ions from extracellular environment to intra cellular environment of the cell to maintain metal ion balance and also dissolves Ab-Cu2+/Zn2+aggregates [125, 126].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [125]
Experimental — accuracy not yet measuredIn the citing paper
“Clioquinol from class 8-hydroxyquinoline has shown better results in treating neurodegenerative disease.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [125]
In the citing paper
“Interaction of metals with Aβ leads to the generation of ROS as well as abnormal metal ion homeostasis which is linked to the pathogenesis of AD.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [125]
In the citing paper
“It is a bi-dentate ligand which has 2:1 activity against copper and zinc ions.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [125]
In the citing paper
“Metal chelators are agents that break the Aβ-metal complex and restore metal ion homeostasis and hence reduce neuro toxicity.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [125]
In the citing paper
“Consequently, the emergence of CQ as an anti-AD drug has been halted due to potential neurotoxicity and undesirable mutagenic contaminants (Budimir et al., 2011).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Budimir et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
3D structure of Alzheimer's amyloid-β(1–42) fibrils
Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Döbeli, H., Schubert, D. A., & Riek, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506723102 · Cited by 2,001
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Research works printed but not linked: 2
- C. P. Ferri, R. Sousa, E. Albanese, W. S. Ribeiro and M. Honyashiki, World Alzheimer Report 2009 - Executive Summary (Eds. M. Prince and J. Jadeson), Alzheimer's Disease International, London 2009, pp. 1-22; http://www.alz.co.uk/adi/publications.html
- R. Cherny, 1999, Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion, J. Biol. Chem, 274, 23223, 10.1074/jbc.274.33.23223 · DOI · Paper page
Cited by
Sorted by citations
Items 201–206 of 206
Development of copper ligands for therepeutic applications
Balderrama-Martínez-Sotomayor, R. (2020) · theses.fr (ABES) · doi:10.70675/449f1d52z9b40z487cza9cczb4edaf3b75f1
Development of chelating materials for localized metal extraction in neurodegenerative diseases
Ariza, J. F. S. (2024) · theses.fr (ABES) · doi:10.70675/f7b37b1dz1608z4009zae5cz453748e7aaaf
Ali, S. H., Nazhad, A., Osmani̇ye, D., & Sağlık, B. N. (2026) · European Journal of Life Sciences · doi:10.55971/ejls.1737133
BindingDB Entry 50048240: Neuritogenic activity of bi-functional bis-tryptoline triazole.
BindingDB (2018) · UC San Diego · doi:10.7270/q2k07675
Metadata
- Authors
- Budimir, A.
- Affiliations
- University of Zagreb (HR)
- Corresponding author
- Budimir, Ana
- ORCID
- Budimir, Ana
- Venue
- Acta Pharmaceutica
- Publisher
- Walter de Gruyter GmbH
- Published
- 2011-03-01
- Volume
- 61
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1330-0075 (ISSN-L)
- 1846-9558
- OpenAlex
- W2033807567
- Cited by
- 202
- References
- 75
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 13 · 2023: 12 · 2022: 14 · 2021: 18 · 2020: 18 · 2019: 15 · 2018: 19 · 2017: 13 · 2016: 18 · 2015: 12 · 2014: 14 · 2013: 12 · 2012: 12
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Acta Pharmaceutica (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Zagreb University Computing Centre (SRCE) (submittedVersion, other-oa)
- Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- metal ions, Alzheimer's disease, chelation therapy, metal chelators, neurodegeneration, metal homeostasis, Parkinson's disease, metal imbalance
- MeSH terms
- Alzheimer Disease, Animals, Chelating Agents, Homeostasis, Humans, Hydroxyquinolines, Ions, Metals, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
